Immutep Completes A$6M Entitlement Offer
August 06 2019 - 8:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”) is pleased to announce the completion of its fully
underwritten pro rata non-renounceable entitlement offer
(“Entitlement Offer”) of new fully paid ordinary shares in Immutep
(“New Shares”) which closed at 5.00pm AEST on Tuesday, 30 July
2019. The Entitlement Offer allowed eligible shareholders the
opportunity to subscribe for one New Share for every 11.8 existing
Immutep shares held as at the record date.
Applications from eligible retail shareholders under the
Entitlement Offer (including applications for additional New Shares
in the shortfall facility, up to A$20,000) totalled 129,580,499 New
Shares at A$0.021 per New Share.
In accordance with the underwriting agreement between Immutep
and an Australian underwriter, the underwriter subscribed for
157,588,849 New Shares under the shortfall.
The A$6 million raised under the fully underwritten Entitlement
Offer together with the A$4 million placement to institutional
investors announced on Tuesday, 9 July 2019, brings the total
capital raised to A$10.0 million and is expected to extend the
Company’s cash runway to the end of calendar year 2020.
These funds will be used by the Company to drive the development
of its immuno-oncology and autoimmune programs and to pursue
regulatory pathways for its lead product candidate, eftilagimod
alpha.
The Entitlement Offer included management team and director
participation from Immutep.
The New Shares issued under the Entitlement Offer were issued
today and rank equally with existing Immutep shares on issue.
Trading in the New Shares is expected to commence on ASX on a
normal settlement basis tomorrow on Wednesday, 7 August 2019.
About Immutep
Further information can be found on the
Company’s website www.immutep.com or by contacting:
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
U.S. Investors:Jay Campbell,
Chief Business Officer, Immutep Limited+1 (917) 860-9404;
jay.campbell@immutep.com
This announcement does not constitute an offer
to sell, or the solicitation of an offer to buy, any securities in
the United States. The securities issued under the Entitlement
Offer have not been registered under the US Securities Act of 1933
and may not be offered or sold in the United States or to US
Persons (as defined in Rule 902(k) under the US Securities Act)
except in transactions registered under the US Securities Act or
pursuant to an exemption from, or in transactions not subject to,
the registration requirements of the US Securities Act of 1933 and
any applicable US state securities laws
This announcement may include forward-looking statements. These
forward-looking statements are based on Immutep’s expectations and
beliefs concerning future events. Forward looking statements are
necessarily subject to risks, uncertainties and other factors, many
of which are outside the control of Immutep, which could cause
actual results to differ materially from such statements. Immutep
makes no undertaking to subsequently update or revise the
forward-looking statements made in this announcement, to reflect
the circumstances or events after the date of this
announcement.
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jul 2023 to Jul 2024